TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20887742
Drug: Protein-rich supplements
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein-rich supplements (80±21g protein intake)
Study: 20887742
Drug: Isoenergetic combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoenergetic combination of carbohydrate and fat supplements (59±11g protein intake)
Study: 20887742
Drug: Protein-rich supplements
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein-rich supplements
Study: 20887742
Drug: Isoenergetic combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoenergetic combination of carbohydrate and fat supplements
Study: 14508205
Drug: Lercanidipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lercanidipine (20 mg daily)
Study: 8619389
Drug: Estrogen plus
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen plus UFT (400 mg/day: group B)
Study: 8619389
Drug: Estrogen alone
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen alone (Honvan 200 mg/day or presexol 1 mg/day: group A)
Study: 4015740
Drug: Suprofen 200
Normalized name: suprofen 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suprofen 200 mg/ml i.m. (3 injections/day for 7 days)
Study: 4015740
Drug: Diclofenac 25
Normalized name: diclofenac 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 25 mg/ml i.m. (3 injections/day for 7 days)
Study: 4015740
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 injections/day for 7 days)
Study: 31272477
Drug: Antipsychotics (APs)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotics (APs) alone
Study: 31272477
Drug: Psychological Interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychological Interventions (PI) alone (Cognitive Behavioural Therapy and Family Intervention)
Study: 31272477
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Antipsychotics and Psychological Interventions
Study: 30058395
Drug: Dialectical Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical Behavioral Therapy‐Corrections Modified (DBT‐CM)
Study: 26863321
Drug: Yoga practice
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga practice frequency after treatment
Study: 22157329
Drug: Acotiamide 100
Normalized name: acetiamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acotiamide 100 mg three times a day for 4 weeks
Study: 22157329
Drug: Acotiamide 100
Normalized name: acetiamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acotiamide 100 mg
Study: 15816570
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: 3 mL demand dose with 6 min lockout interval
Study: 15816570
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: 6 mL demand dose with 12 min lockout interval
Study: 15816570
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: 9 mL demand dose with 18 min lockout interval
Study: 12774848
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine (400 mL, 279.6 mg total anthocyanins)
Study: 12774848
Drug: Red grape
Normalized name: CVS Children's Cold & Cough Elixir (Red Grape)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red grape juice (400 mL, 283.5 mg total anthocyanins)
Study: 10563230
Drug: Prophylactic drugs
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic drugs (metoprolol, divalproex, amitriptyline, atenolol, flunarizine, naproxen)
Study: 8740095
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg cefpodoxime proxetil (reference)
Study: 8740095
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg cefpodoxime and 200 mg acetylcysteine (test)
Study: 24147869
Drug: On-demand alverine
Normalized name: alverine
DrugBank: Alverine (DB01616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand alverine citrate/simeticone (ACS) treatment
Study: 24147869
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment (mainly antispasmodics)
Study: 15574551
Drug: Aprotinin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (2 x 10(6) KIU loading dose, 2 x 10(6) KIU added to circuit prime, continuous infusion of 5 x 10(5) KIU/hr)
Study: 9832483
Drug: Combination diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination diet (rich in fruits, vegetables, and low-fat dairy products, reduced in fat)
Study: 8126691
Drug: Disclosure induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disclosure induction (three weekly 20-min individual sessions discussing a stressful topic)
Study: 412099
Drug: Trimethoprim-sulfamethoxazole (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (150 mg of trimethoprim and 750 mg of sulfamethoxazole per square meter per day)
Study: 27836905
Drug: Continuous femoral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous femoral nerve block (CFNB) with ropivacaine infusion for 2 days and oxycodone
Study: 27836905
Drug: Intravenous patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous patient-controlled analgesic (IV PCA) of morphine
Study: 19928391
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg of MDMA
Study: 15217028
Drug: Telephone-based problem-solving
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-based problem-solving therapy
Study: 12539568
Drug: Propofol (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (0.1 mg.kg‐1.min‐1)
Study: 9416719
Drug: Patient-controlled interscalene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled interscalene analgesia (PCIA) with 0.15% bupivacaine, continuous infusion at 5 ml/h plus bolus of 3 or 4 ml with a lock-time of 20 min.
Study: 9416719
Drug: Intravenous patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous patient-controlled analgesia (PCA) with nicomorphine, continuous infusion at 0.5 mg/h plus bolus of 2 or 3 mg with a lock-time of 20 min.
Study: 3815837
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose Bupivacaine (50 mg)
Study: 3815837
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose Bupivacaine (25 mg)
Study: 3815837
Drug: Oxytocin administration
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin administration during the block
Study: 3815837
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of Bupivacaine
Study: 18089634
Drug: Pamidronate 12
Normalized name: Pamidronate
DrugBank: Pamidronic acid (DB00282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pamidronate 12 mg/kg/year
Study: 18089634
Drug: Pamidronate 6
Normalized name: pamidronate 6 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate 6 mg/kg/year
Study: 18089634
Drug: Pamidronate (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (both doses)
Study: 16968913
Drug: Primaquine phosphate
Normalized name: Primaquine Phosphate
DrugBank: Primaquine (DB01087)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Primaquine phosphate (30 mg base daily for 14 days for PART; 30 mg daily for primary prophylaxis)
Study: 9352971
Drug: Intravenous conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous conjugated estrogens (0.625 mg)
Study: 28730396
Drug: FRIENDS for
Normalized name: Aluminum Zirconium Tetrachlorohydrex GLY 17.8 g in 100 g TOPICAL STICK [DEGREE GIRL FRIENDS FOREVER ANTIPERSPIRANT AND DEODORANT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: FRIENDS for Life intervention administered by trained teachers
Study: 26360125
Drug: Once-daily extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily extended-release tacrolimus
Study: 24678064
Drug: Topical cocaine
Normalized name: cocaine Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cocaine
Study: 24678064
Drug: Topical adrenaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical adrenaline
Study: 21308791
Drug: Atorvastatin and
Normalized name: atorvastatin and ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin and ezetimibe on top of oral anticoagulation therapy
Study: 20519663
Drug: Metformin (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (n = 125, IDPP-1)
Study: 20519663
Drug: LSM +
Normalized name: Lisdexamfetamine
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LSM + Metformin (n = 121, IDPP-1)
Study: 18509244
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 administration for 6 months
Study: 3168077
Drug: alpha‐2b interferon
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha‐2b interferon treatment (5 IU three times weekly by subcutaneous injection for 16 weeks)
Study: 3168077
Drug: alpha‐2b interferon
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha‐2b interferon treatment
Study: 29871264
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate aqueous nasal spray combined with montelukast (MOM+M)
Study: 29871264
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate aqueous nasal spray combined with loratadine (MOM+L)
Study: 29871264
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate aqueous nasal spray (MOM)
Study: 21466700
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment (simple end-to-end repair of the tendon with no augmentation)
Study: 18050368
Drug: Etidronate disodium
Normalized name: Etidronate Disodium
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etidronate disodium (200 mg per day for 2 weeks) with 3.0 g of calcium lactate and 0.75 microg of alphacalcidol daily
Study: 10852452
Drug: Raloxifene (Evista,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (Evista, 60 mg/day)
Study: 10852452
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens (CEE; Premarin, 0.625 mg/day)
Study: 8096389
Drug: Transdermal glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal glyceryl trinitrate patches releasing 15 mg/24 h
Study: 27386644
Drug: Zaozhu Yinchen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zaozhu Yinchen Recipe (ZZYCR), one dose per day for 24 weeks
Study: 27386644
Drug: Silibin Meglumine
Normalized name: Meglumine
DrugBank: Meglumine (DB09415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Silibin Meglumine Tablets, 20 mg thrice per day for 24 weeks
Study: 12821739
Drug: High-dose cooling
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cooling therapy for 1 hour
Study: 12821739
Drug: Low-dose cooling
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cooling therapy for 1 hour
Study: 12821739
Drug: Daily cooling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily cooling garment use for 1 hour each day for a month
Study: 10834668
Drug: Alfentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil at a target plasma concentration of 100 ng/mL
Study: 10834668
Drug: Alfentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil at a target plasma concentration of 200 ng/mL
Study: 31437195
Drug: Blood loss
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood loss 500-999 ml
Study: 15934285
Drug: Specific immunotherapy
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific immunotherapy and IFN‐gamma treatment (1000000 IU im qod)
Study: 15934285
Drug: Specific immunotherapy
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific immunotherapy (control group)
Study: 12468782
Drug: Doxycycline 200
Normalized name: doxycycline 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 200 mg/d for 2 to 8 weeks
Study: 9785786
Drug: Epidural anesthesia
Normalized name: Epidural Anesthesia Tray
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural anesthesia with propofol (1 mg.kg‐1 bolus followed by 4 mg.kg‐1.h‐1 continuous infusion)
Study: 9785786
Drug: Spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anesthesia with propofol (1 mg.kg‐1 bolus followed by 4 mg.kg‐1.h‐1 continuous infusion)
Study: 7894881
Drug: Antidepressant alone
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant alone (placebo)
Study: 327623
Drug: Primary radiation
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary radiation therapy for stage I cases without randomization, followed or not by maintenance chemotherapy.
Study: 327623
Drug: Mantle field
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mantle field therapy for supradiaphragmatic stage II, followed if necessary by prophylactic infradiaphragmatic irradiation.
Study: 327623
Drug: Two regimens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two regimens of maintenance chemotherapy for all stages II, randomized.
Study: 327623
Drug: Two regimens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two regimens of induction chemotherapy for stages III and IV, followed by maintenance chemotherapy.
Study: 31553134
Drug: Azilsartan (AZL)
DrugBank: Azilsartan medoxomil (DB08822)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azilsartan (AZL) 20 mg single dose
Study: 31553134
Drug: Azilsartan (AZL)
DrugBank: Azilsartan medoxomil (DB08822)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azilsartan (AZL) 40 mg single dose
Study: 31553134
Drug: Azilsartan (AZL)
DrugBank: Azilsartan medoxomil (DB08822)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azilsartan (AZL) 40 mg/d for 7 days (multiple doses)
Study: 31553134
Drug: Azilsartan (AZL)
DrugBank: Azilsartan medoxomil (DB08822)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azilsartan (AZL) 40 mg single dose under fasted and fed conditions
Study: 31696504
Drug: Probiotic group
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic group (42 patients, 10M/32F, mean age 32.23 ± 10.3 years) treated with ciprofloxacin 400 mg twice a day and metronidazole 500 mg three times a day for one week, supplemented with probiotic mix (1 sachet twice a day for 10 days)
Study: 31696504
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (42 patients, 15M/27F, mean age 59.01 ± 11.3 years) received the same antibiotic treatment without the probiotic mix
Study: 24235233
Drug: Chlorine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorine (200 mg/kg)
Study: 21470834
Drug: Higher prescribed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher prescribed dose
Study: 14660997
Drug: HMG CoA
Normalized name: HMG CoA reductase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMG CoA reductase inhibitors
Study: 8989069
Drug: Fluconazole (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (3 mg/kg daily orally) and placebo (100 mg/kg/daily orally)
Study: 8989069
Drug: Itraconazole (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (3 mg/kg daily orally) and flucytosine (100 mg/kg daily orally)
Study: 8989069
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 mg/kg daily orally) and placebo (100 mg/kg daily orally)
Study: 1453306
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg ibuprofen immediately presurgically
Study: 1453306
Drug: Placebo before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo before surgery and 600 mg ibuprofen postsurgically
Study: 2981982
Drug: High-dose cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cisplatin and vindesine (PVD)
Study: 23926117
Drug: Ezetimibe/Simvastatin (E/S)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe/Simvastatin (E/S) + Niacin (N) (10/20 mg/day + titrated to 2 g/day)
Study: 23926117
Drug: Niacin (N)
Normalized name: Niacin
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin (N) (titrated to 2 g/day)
Study: 23926117
Drug: Ezetimibe/Simvastatin (E/S)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe/Simvastatin (E/S) (10/20 mg/day)
Study: 21874559
Drug: bilastine 50
Normalized name: bilastine
DrugBank: Bilastine (DB11591)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: bilastine 50 mg
Study: 21874559
Drug: bilastine 20
Normalized name: Bilastine 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: bilastine 20 mg
Study: 19903187
Drug: Multiple-dose LRPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose LRPT 40 mg/day for 7 days coadministered with single-dose rosiglitazone 4 mg
Study: 19903187
Drug: Single-dose rosiglitazone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose rosiglitazone 4 mg
Study: 17257457
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac epolamine plaster (DHEP)
Study: 12939586
Drug: Initial treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial treatment (various methods including vasoactive drugs, endoscopic therapy, combined therapy, balloon tamponade)
Study: 11466698
Drug: BCNU (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCNU (150 mg/m(2) on Day 3) plus IFN‐alpha (12 million U/m(2) on Days 1‐3, Weeks 1, 3, and 5) every 7 weeks for a maximum of 6 cycles
Study: 11466698
Drug: BCNU alone
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BCNU alone (200 mg/m(2) on Day 1)
Study: 28326881
Drug: Probiotic supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplementation (Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum, 2 × 10^9 CFU/g each) for six weeks
Study: 9085960
Drug: Morphine (0.75,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.75, 1.0, or 1.5 mg bolus dose size)
Study: 9085960
Drug: Meperidine (9,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine (9, 12, or 18 mg)
Study: 9085960
Drug: Morphine and
Normalized name: morphine and antispasmodics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine and Meperidine
Study: 8448101
Drug: Articaine 4%
Normalized name: ARTICAINE 4%/EPI 1:200000 INJ CART 1.7ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Articaine 4% with 20 micrograms epinephrine (2 mL)
Study: 2891754
Drug: Metronidazole (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (500 mg intravenous intra-operative dose)
Study: 27815079
Drug: AnisEncap (enteric
Approvals — FDA: no, EMA: no, PMDA: no
Description: AnisEncap (enteric coated capsules of anise oil)
Study: 23270200
Drug: no foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: no foam (blank patch)
Study: 356252
Drug: Inhaled RS
Normalized name: (RS)-bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled RS 7540 (40 mg)
Study: 356252
Drug: Inhaled RS
Normalized name: (RS)-bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled RS 7540 (20 mg)
Study: 27217047
Drug: Tacrolimus with
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus with azole antifungal agents (AZ)
Study: 27217047
Drug: Tacrolimus without
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus without azole antifungal agents (AZ)
Study: 22250191
Drug: Selective BRAF
Normalized name: Braftovi
DrugBank: Encorafenib (DB11718)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Selective BRAF inhibitors
Study: 22250191
Drug: Analgesic and
Normalized name: otologic analgesic and anesthetic combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic and anti-inflammatory treatment (e.g., etoricoxib)
Study: 22250191
Drug: Dose reduction
Normalized name: Rebetron Combination Package for Rebetol Dose Reduction, Intron A 6,000,000 UNT/ML Multi-Dose Vial / 42 Rebetol Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose reduction of BRAF inhibitor
Study: 17645554
Drug: Sulphonylurea treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphonylurea treatment in addition to dietary regulation and increased exercise
Study: 15955935
Drug: Gabapentin (GBP)
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin (GBP) 1,500 mg/day
Study: 15955935
Drug: Lamotrigine (LTG)
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine (LTG) 150 mg/day
Study: 11839708
Drug: Adrenaline injection
Normalized name: epinephrine Injection [Adrenalin]
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adrenaline injection plus heater probe thermocoagulation
Study: 10405498
Drug: Adderall (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adderall (single dose)
Study: 10405498
Drug: Methylphenidate (2
Normalized name: methylphenidate (20/80 release) 25 mg/24 hr oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (2 daily doses)
Study: 7749423
Drug: High-CHO diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-CHO diet of 10.52 +/‐ 0.57 g/kg body mass/day
Study: 7749423
Drug: Normal CHO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal CHO intake of 6.15 +/‐ 0.23 g/kg body mass/day
Study: 2309227
Drug: Intrapleural bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapleural bupivacaine (20 ml of 0.25% bupivacaine for 48 hours)
Study: 398485
Drug: Ampicillin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin (50 mg/kg/day in 4 divided doses for 5 days)
Study: 398485
Drug: Cefaclor (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor (50 mg/kg/day in 3 divided doses for 5 days)